These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 12228912

  • 1. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects.
    Buendia MA.
    Med Pediatr Oncol; 2002 Nov; 39(5):530-5. PubMed ID: 12228912
    [Abstract] [Full Text] [Related]

  • 2. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
    Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA, Liu W.
    Oncogene; 2002 Jul 18; 21(31):4863-71. PubMed ID: 12101426
    [Abstract] [Full Text] [Related]

  • 3. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features.
    Wei Y, Van Nhieu JT, Prigent S, Srivatanakul P, Tiollais P, Buendia MA.
    Hepatology; 2002 Sep 18; 36(3):692-701. PubMed ID: 12198663
    [Abstract] [Full Text] [Related]

  • 4. Genetics of hepatocellular carcinoma.
    Buendia MA.
    Semin Cancer Biol; 2000 Jun 18; 10(3):185-200. PubMed ID: 10936068
    [Abstract] [Full Text] [Related]

  • 5. Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome.
    Weber RG, Pietsch T, von Schweinitz D, Lichter P.
    Am J Pathol; 2000 Aug 18; 157(2):571-8. PubMed ID: 10934159
    [Abstract] [Full Text] [Related]

  • 6. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas.
    Wei Y, Fabre M, Branchereau S, Gauthier F, Perilongo G, Buendia MA.
    Oncogene; 2000 Jan 27; 19(4):498-504. PubMed ID: 10698519
    [Abstract] [Full Text] [Related]

  • 7. Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis.
    Nishida N, Nishimura T, Nagasaka T, Ikai I, Goel A, Boland CR.
    Cancer Res; 2007 May 15; 67(10):4586-94. PubMed ID: 17510384
    [Abstract] [Full Text] [Related]

  • 8. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.
    Cazals-Hatem D, Rebouissou S, Bioulac-Sage P, Bluteau O, Blanché H, Franco D, Monges G, Belghiti J, Sa Cunha A, Laurent-Puig P, Degott C, Zucman-Rossi J.
    J Hepatol; 2004 Aug 15; 41(2):292-8. PubMed ID: 15288479
    [Abstract] [Full Text] [Related]

  • 9. Cytogenetic alterations in liver cell tumors as detected by comparative genomic hybridization.
    Terracciano L, Tornillo L.
    Pathologica; 2003 Apr 15; 95(2):71-82. PubMed ID: 12768875
    [Abstract] [Full Text] [Related]

  • 10. Recurrent allelic deletions at mouse chromosomes 4 and 14 in Myc-induced liver tumors.
    Wu Y, Renard CA, Apiou F, Huerre M, Tiollais P, Dutrillaux B, Buendia MA.
    Oncogene; 2002 Feb 28; 21(10):1518-26. PubMed ID: 11896580
    [Abstract] [Full Text] [Related]

  • 11. Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas.
    Koch A, Weber N, Waha A, Hartmann W, Denkhaus D, Behrens J, Birchmeier W, von Schweinitz D, Pietsch T.
    J Pathol; 2004 Dec 28; 204(5):546-54. PubMed ID: 15538750
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors.
    Yamaoka H, Ohtsu K, Sueda T, Yokoyama T, Hiyama E.
    Oncol Rep; 2006 Mar 28; 15(3):551-6. PubMed ID: 16465411
    [Abstract] [Full Text] [Related]

  • 13. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity.
    Legoix P, Bluteau O, Bayer J, Perret C, Balabaud C, Belghiti J, Franco D, Thomas G, Laurent-Puig P, Zucman-Rossi J.
    Oncogene; 1999 Jul 08; 18(27):4044-6. PubMed ID: 10435629
    [Abstract] [Full Text] [Related]

  • 14. Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability.
    Guda K, Upender MB, Belinsky G, Flynn C, Nakanishi M, Marino JN, Ried T, Rosenberg DW.
    Oncogene; 2004 May 06; 23(21):3813-21. PubMed ID: 15021908
    [Abstract] [Full Text] [Related]

  • 15. Y chromosome loss and other genomic alterations in hepatocellular carcinoma cell lines analyzed by CGH and CGH array.
    Park SJ, Jeong SY, Kim HJ.
    Cancer Genet Cytogenet; 2006 Apr 01; 166(1):56-64. PubMed ID: 16616112
    [Abstract] [Full Text] [Related]

  • 16. HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing.
    Yau TO, Chan CY, Chan KL, Lee MF, Wong CM, Fan ST, Ng IO.
    Oncogene; 2005 Feb 24; 24(9):1607-14. PubMed ID: 15580286
    [Abstract] [Full Text] [Related]

  • 17. Cadherin/catenin complex appears to be intact in hepatocellular carcinomas from Australia and South Africa.
    Herath NI, Walsh MD, Kew MC, Young J, Leggett BA, Macdonald GA.
    J Gastroenterol Hepatol; 2004 Jun 24; 19(6):676-82. PubMed ID: 15151624
    [Abstract] [Full Text] [Related]

  • 18. Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets.
    Katoh H, Ojima H, Kokubu A, Saito S, Kondo T, Kosuge T, Hosoda F, Imoto I, Inazawa J, Hirohashi S, Shibata T.
    Gastroenterology; 2007 Nov 24; 133(5):1475-86. PubMed ID: 17983802
    [Abstract] [Full Text] [Related]

  • 19. [Molecular mechanism of hepatocarcinogenesis].
    Imazeki F, Saisho H.
    Gan To Kagaku Ryoho; 1999 Dec 24; 26(14):2154-61. PubMed ID: 10635298
    [Abstract] [Full Text] [Related]

  • 20. Overview of the molecular biology of hepatocellular neoplasms and hepatoblastomas of the mouse liver.
    Kim Y, Sills RC, Houle CD.
    Toxicol Pathol; 2005 Dec 24; 33(1):175-80. PubMed ID: 15805069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.